XML 50 R34.htm IDEA: XBRL DOCUMENT v3.20.2
Share-Based Compensation (Tables)
3 Months Ended
Sep. 30, 2020
Share-based Payment Arrangement [Abstract]  
Schedule of Stock Option Activity
A summary of the stock option activity under the Company’s equity plans, including the Company's inducement awards, for the three months ended September 30, 2020 is as follows:
Number
of
shares
Weighted
average
exercise
price
Options outstanding at June 30, 20204.8 $24.47 
Options granted0.7 $13.38 
Less:
Options exercised— $— 
Options canceled or expired(0.1)$16.40 
Options outstanding at September 30, 20205.4 $23.19 
Options exercisable at September 30, 20204.7 $24.62 
Schedule of Restricted Stock Unit Activity
A summary of the RSU activity under the Company’s plans, including the Company's inducement awards and RSU awards with performance metrics, for the three months ended September 30, 2020 is as follows:
Number
of
shares
Weighted
average
grant date
fair value
RSUs outstanding at June 30, 20202.3 $32.50 
RSUs granted0.4 $13.24 
Less:
RSUs vested(0.8)$33.07 
RSUs canceled— $— 
RSUs outstanding at September 30, 20201.9 $27.70 
Schedule of Share-Based Compensation Expense
Share-based compensation expense recognized and included in the condensed consolidated statements of operations and comprehensive loss was allocated as follows:
Three months ended
September 30,
20202019
Cost of molecular diagnostic testing$0.3 $0.2 
Cost of pharmaceutical and clinical services0.1 0.1 
Research and development expense1.3 1.5 
Selling, general, and administrative expense6.7 7.0 
     Total share-based compensation expense$8.4 $8.8